ストックスクリーナーアプリを入手
17.80
3.43%
0.59
前日終値:
$17.21
開ける：
$17.25
24時間の取引高:
1.79M
Relative Volume:
0.98
時価総額：
$2.46B
収益：
$181.74M
当期純損益:
$-143.97M
株価収益率:
-12.81
EPS:
-1.39
ネットキャッシュフロー:
$9.60M
1週間 パフォーマンス:
+8.08%
1か月 パフォーマンス:
-2.79%
6か月 パフォーマンス:
-4.15%
1年 パフォーマンス:
-22.41%
1日の値動き範囲:
$17.22
$18.13
1週間の範囲:
$15.01
$18.13
52週間の値動き範囲:
$9.57
$27.34
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
ARWR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
17.80 | 2.38B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Call Transcript - Insider Monkey
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt? - 富途牛牛
Arrowhead Pharmaceuticals’ Earnings Call Highlights Strategic Progress - TipRanks
Arrowhead Pharmaceuticals Advances RNAi Therapeutics Pipeline - TipRanks
Arrowhead Pharma's Analyst Rating and Price Target Maintained at $60.00 - AInvest
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Arrowhead reports Q3 EPS ($1.26), consensus ($1.10) - TipRanks
ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS - Research Tree
Is Arrowhead Pharmaceuticals Inc. trending in predictive chart modelsStock Market Watch with Smart Filters - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals: A High-Conviction Biotech Play with Multi-Billion-Dollar Potential - AInvest
Quoin (QNRX) Q2 Loss Beats Estimates - AOL.com
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $29 to $45 - 富途牛牛
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Arrowhead Pharma stock price target lowered to $21 at Leerink Partners - Investing.com Canada
Arrowhead Pharmaceuticals: Balancing Promising Launch Preparations with Pipeline Uncertainties - TipRanks
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts - Investing.com
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts By Investing.com - Investing.com Canada
Arrowhead (ARWR) Q3 Revenue Drops 41% - AOL.com
Arrowhead Pharmaceuticals: Navigating a Narrowing Loss and a Pivotal Regulatory Timeline for Plozasiran - AInvest
Arrowhead Pharmaceuticals Fiscal Q3 Loss Narrows, Reports Revenue - MarketScreener
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals: Buy Rating Affirmed on Promising Pipeline and Late-Stage Developments - TipRanks
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript - Mitrade
ARROWHEAD PHARMACEUTICALS Earnings Results: $ARWR Reports Quarterly Earnings | ARWR Stock News - Quiver Quantitative
Arrowhead Pharmaceuticals Q3 Revenue Surpasses Expectations with $27.8mln, Sarepta Milestone Earnings $100mln. - AInvest
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results - Business Wire
Arrowhead Pharmaceuticals shares fall 2.15% intraday as Sarepta Therapeutics reports strong earnings and resumes deliveries. - AInvest
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Prepares for Q3 Earnings Report - GuruFocus
TR | OpenAI4o Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $16.5 - 富途牛牛
Arrowhead sells rights of Hypertriglyceridemia candidate to Sanofi in Greater China for $265 M - BioSpectrum Asia
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi - Yahoo Finance
Sanofi grabs Chinese rights to Arrowhead rare disease drug - pharmaphorum
Is Arrowhead Pharmaceuticals Inc. a growth stock or a value stockFree Daily Trading Room Entry - Jammu Links News
Is Arrowhead Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough investment performance - Jammu Links News
When is Arrowhead Pharmaceuticals Inc. stock expected to show significant growthBuild a diversified portfolio for sustainable growth - Jammu Links News
How volatile is Arrowhead Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough investment performance - Jammu Links News
Is it the right time to buy Arrowhead Pharmaceuticals Inc. stockPhenomenal returns - Jammu Links News
What are the latest earnings results for Arrowhead Pharmaceuticals Inc.Achieve consistent high returns with low risk - Jammu Links News
Why is Arrowhead Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on emerging investment opportunities - Jammu Links News
Should I hold or sell Arrowhead Pharmaceuticals Inc. stock in 2025Unlock powerful trading strategies for gains - Jammu Links News
What are Arrowhead Pharmaceuticals Inc. company’s key revenue driversBreakthrough wealth creation - Jammu Links News
What analysts say about Arrowhead Pharmaceuticals Inc. stockOutstanding yields - Jammu Links News
How does Arrowhead Pharmaceuticals Inc. compare to its industry peersMaster the art of timing market moves - Jammu Links News
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
0.91%
3.06%
大文字化:
|
ボリューム (24 時間):